Discussing the Dysfunction in MGD and DED (CME Webcast)
Activity Description and Purpose
Meibomian gland dysfunction (MGD) is the root cause of dry eye disease (DED), leading to poor tear film quality and exacerbated evaporation of the tear film from the ocular surface. Diagnosis of DED is often delayed, and, until recently, available prescription-based treatments did not target evaporative loss. In this educational activity, experts will present real-world cases that review best practices in the diagnosis and management of MGD-associated DED and current treatment strategies and discuss emerging treatments for MGD. This educational activity is based on the proceedings of a series of live CME/CE webinars. Since these proceedings, perfluorohexyloctane, 100%, and TP-03 have been approved by the US Food and Drug Administration for the treatment of DED and Demodex blepharitis, respectively. The desired results of this activity are to cement knowledge of the pathophysiology of MGD-associated DED and to help ophthalmologists obtain practical strategies for screening, diagnosis, and effective treatment that can improve outcomes for patients.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Incorporate routine meibomian gland expression into practice
- Describe the pathophysiology of meibomian gland dysfunction–associated dry eye disease
- Design evidence-based treatment plans for persons with meibomian gland dysfunction–associated dry eye disease
- Evaluate clinical trial data for agents under development for the treatment of meibomian gland dysfunction–associated dry eye disease
|Kendall E. Donaldson, MD, MS
Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute in Plantation
|Walter O. Whitley, OD, MBA, FAAO
Director, Optometric Services
Virginia Eye Consultants
Virginia Beach, Virginia
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Kendall E. Donaldson, MD, MS, is a consultant for AcuFocus, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Omeros Corporation, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Zeiss.
Walter O. Whitley, OD, MBA, FAAO, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Santen Inc, Sun Pharmaceutical Industries, Inc, and ScienceBased Health; and is on the speakers bureau of Alcon, Allergan, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Oyster Point Pharma, Inc, Santen Inc, and Sun Pharmaceutical Industries, Inc.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.
©2023 MedEdicus LLC. 279.2
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation